Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Appointment of New Chief Financial Officer
Toggle Summary Intersect ENT to Present at the 31st Annual Piper Jaffray Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 19, 2019-- Intersect ENT, Inc. (NASDAQ: XENT ) today announced that management will participate in the 31 st Annual Piper Jaffray Healthcare Conference on December 4 at the Lotte New York Palace Hotel in New York City , and will present in a session at
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019 .
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 17, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release third quarter financial results on November 1, 2019 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2019 Results
CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 15, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019 .
View HTML
Toggle Summary Intersect ENT Announces Appointment of Thomas A. West as CEO
Toggle Summary Intersect ENT Announces Publication of a Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps
Toggle Summary Intersect ENT Reports First Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 6, 2019-- Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Intersect ENT Announces CEO Transition Plan